Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1995 Aug;41(2):82-6.
doi: 10.1007/BF01527403.

Cytokine-gene-modified tumor vaccination intensified by a streptococcal preparation OK-432

J Abe  1 , H Wakimoto, M Aoyagi, K Hirakawa, H Hamada
Affiliations

Cytokine-gene-modified tumor vaccination intensified by a streptococcal preparation OK-432

J Abe et al. Cancer Immunol Immunother. 1995 Aug.

Abstract

Vaccinations with tumor cells engineered to express certain cytokines have been demonstrated to induce potent and specific antitumor immunity. In our previous report, we carried out a comparative study on the ability of cytokine-gene-modified tumor vaccines to induce host immune responses, and found that irradiated tumor cells, genetically modified to secrete granulocyte/macrophage-colony-stimulating factor (GM-CSF tumor vaccine), were the most potent stimulators of systemic antitumor immunity. In this report, using the experimental tumor models in which the GM-CSF tumor vaccine was less effective in immunopotentiation, we found that the combined use of a biological response modifier (BRM) OK-432 remarkably enhanced the antitumor activity induced by the GM-CSF tumor vaccine. These data indicate the possible role of a BRM such as OK-432 to intensify further the specific tumor vaccination therapy.

PubMed Disclaimer

References

    1. Abe J, Wakimoto H, Nakamura Y, Kanegae Y, Saito I, Aoyagi M, Hirakawa K, Hamada H. Immunogene therapy for cancer by cytokine gene-modified tumor vaccine and tumor-infiltrating lymphocytes (TIL) Cancer Gene Therapy. 1994;1:312.
    1. Anderson WF. Gene therapy for cancer. Hum Gene Ther. 1994;5:1. - PubMed
    1. Aoki T, Tashiro K, Miyatake S, Kinashi T, Nakano T, Oda Y, Kikuchi H, Honjo T. Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo. Proc Natl Acad Sci USA. 1992;89:3850. - PMC - PubMed
    1. Asher AL, Mule JJ, Kasid A, Restifo NP, Solo JC, Reichert CM, Jaffe G, Fendly B, Kriegler M, Rosenberg SA. Murine tumor cells transduced with the gene for tumor necrosis factor-α. J Immunol. 1991;146:3227. - PMC - PubMed
    1. Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, McGowan P, Linsley PS. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecule CD28 and CTLA-4. Cell. 1992;71:1093. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources